Highlights
- CND Life Sciences, Inc. raised $6.32 million in a private securities offering, with first sale dated June 9, 2026.
- The Scottsdale-based biotech's amended Form D shows 14 investors participated, none of them non-accredited.
- Six named principals appear on the filing, including executive officers Richard Morello, Todd Levine, and Peter Harris.
- The offering is fully closed, with $0 remaining of the $6.32 million target.
CND Life Sciences, Inc., a Delaware-incorporated biotech operating out of 9165 E. Del Camino Drive, Suite 101, in Scottsdale, closed a $6.32 million private securities offering, according to an amended Form D filed with the SEC on Aug. 3, 2026.
The filing shows the total amount sold matches the target offering amount of $6.32 million, leaving $0 remaining. First sale was recorded June 9, 2026. The minimum investment accepted was $25,000.
Fourteen investors participated in the round, according to the filing. The company reported no non-accredited investors among them.
Six individuals are listed as related persons on the filing. Richard Morello, Todd Levine, and Peter Harris are each identified as executive officers and directors. Enrique Carrazana, Christopher Gibbons, and Jack Seaver are listed as directors. The filing does not disclose lead investor identity or post-money valuation.
CND Life Sciences carries CIK 0001841099 with the SEC and EIN 82-1795059, according to tax ID records. The company's fiscal year ends December 31.
Form D filings cover exempt private offerings and do not require the same disclosures as registered securities. The filing does not describe the company's use of proceeds or its specific business activities beyond the biotechnology industry classification.
No prior Signal coverage of CND Life Sciences exists in our database. The company's next required SEC disclosure would follow any material change to the offering or a subsequent capital raise.
Sources
Every factual claim in this article traces to one of the sources below. See how we work for the editorial process.
- SEC EDGAR retrieved 04/08/2026 14:48
- eintaxid.com retrieved 04/08/2026 14:48
Authored by The Scottsdale Signal. Drafted by AI from primary-source material under our beat-specific editorial guides; reviewed by humans before publish under our five-gate process. Sources retrieved at 04/08/2026 14:48. Every claim traces to a source.
